Transcript levels of MAPK, NIK, NLR and SA-dependent gene pathways and responsive genes. by Bulelani L. Sizani (21485746)

Subjects:

Differentially-expressed NLR genes in susceptible T200 and tolerant TME3 genotypes infected with SACMV. by Bulelani L. Sizani (21485746)

Subjects:

Total count of HiFi reads indicating gene variation in 24 cassava genotypes. by Bulelani L. Sizani (21485746)

Subjects:

Hypothetical model of the molecular mechanism underlying the ability of SACMV to suppress the host RNA silencing mechanism (PTGS) and systemic acquired resistance (SAR). by Bulelani L. Sizani (21485746)

Subjects:

Path analysis diagram illustrating the associations between alexithymia, social support, anticipated stigma and patient satisfaction, with their respective correlation coefficients... by Keya Bibikar (22386306)

P values of Kruskal–Wallis test at 95% significance level. by Fahd Saeed Alakbari (10701871)

Subjects:

Table 1_Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver dise... by Elżbieta Supruniuk (16736637)

Table 2_Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver dise... by Elżbieta Supruniuk (16736637)

S1 File - by Ingmar Lundquist (46422)

“…Additionally, the significance of extracellular NO on GSIS was studied. …”

<i>N. parisii</i> infection is not significantly changed in <i>C. elegans</i> sphingolipid biosynthesis mutants. by Hala Tamim El Jarkass (16625309)

Subjects:

Effect of imidacloprid (Im) and rutin (Ru) administration on thoracic electric currents in Africanized honey bee foragers. by Juan P. Hernández (22216133)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects: